Structured Review

Novus Biologicals anti sphk1 antibody
Gene and protein expression of components of the PAR-1/SphK/S1P axis. qRT-PCR analysis of the gene expression of (A) PAR-1, (B) S1PR1, (C) <t>SphK1,</t> and (D) SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for 0 h, 1 h, or 6 h. Western blot detection and quantification of the protein expression of PAR-1, S1PR1, SphK1, and SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for (E) 0 h, (F) 1 h, or (G) 6 h. The data are presented as the mean ± SD ( n = 3), * p
Anti Sphk1 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 96/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti sphk1 antibody/product/Novus Biologicals
Average 96 stars, based on 2 article reviews
Price from $9.99 to $1999.99
anti sphk1 antibody - by Bioz Stars, 2022-10
96/100 stars

Images

1) Product Images from "Dabigatran Suppresses PAR-1/SphK/S1P Activation of Astrocytes in Experimental Autoimmune Encephalomyelitis Model"

Article Title: Dabigatran Suppresses PAR-1/SphK/S1P Activation of Astrocytes in Experimental Autoimmune Encephalomyelitis Model

Journal: Frontiers in Molecular Neuroscience

doi: 10.3389/fnmol.2020.00114

Gene and protein expression of components of the PAR-1/SphK/S1P axis. qRT-PCR analysis of the gene expression of (A) PAR-1, (B) S1PR1, (C) SphK1, and (D) SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for 0 h, 1 h, or 6 h. Western blot detection and quantification of the protein expression of PAR-1, S1PR1, SphK1, and SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for (E) 0 h, (F) 1 h, or (G) 6 h. The data are presented as the mean ± SD ( n = 3), * p
Figure Legend Snippet: Gene and protein expression of components of the PAR-1/SphK/S1P axis. qRT-PCR analysis of the gene expression of (A) PAR-1, (B) S1PR1, (C) SphK1, and (D) SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for 0 h, 1 h, or 6 h. Western blot detection and quantification of the protein expression of PAR-1, S1PR1, SphK1, and SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for (E) 0 h, (F) 1 h, or (G) 6 h. The data are presented as the mean ± SD ( n = 3), * p

Techniques Used: Expressing, Quantitative RT-PCR, Western Blot

Construction of the in vivo experimental autoimmune encephalomyelitis (EAE) model. Experimental mice were induced by EAE and treated with physiological saline (vehicle), 10 mg/g Dab, or 10 μg/kg PAR-1-inh. (A) Clinical evaluation of neurological function was carried out daily for over 30 days. 0, unaffected; 1, tail limpness; 2, failure on attempt to roll over; 3, partial paralysis; 4, complete paralysis, and 5, moribund. Data are presented as the mean ± SD of six replicates. Western blot evaluation and quantification of the protein expression of (B) IL-1β, S1P, (C) SphK1, and SphK2 in spinal cord tissues after 30 days of EAE modeling, with or without treatment. (D) Hematoxylin and eosin (H E) and luxol fast blue (LFB) staining of spinal cord tissue 30 days after EAE modeling, with or without treatment. Arrows point to pink areas indicative of inflammatory infiltration. The intensity of blue color in the LFB images represents the degree of demyelination (lighter = greater demyelination). Mag = magnification of specific areas of interest in LFB images. Scale bar = 100 μm for H E and 50 μm for LFB. For (B,C) , the data are presented as the mean ± SD ( n = 6), * p
Figure Legend Snippet: Construction of the in vivo experimental autoimmune encephalomyelitis (EAE) model. Experimental mice were induced by EAE and treated with physiological saline (vehicle), 10 mg/g Dab, or 10 μg/kg PAR-1-inh. (A) Clinical evaluation of neurological function was carried out daily for over 30 days. 0, unaffected; 1, tail limpness; 2, failure on attempt to roll over; 3, partial paralysis; 4, complete paralysis, and 5, moribund. Data are presented as the mean ± SD of six replicates. Western blot evaluation and quantification of the protein expression of (B) IL-1β, S1P, (C) SphK1, and SphK2 in spinal cord tissues after 30 days of EAE modeling, with or without treatment. (D) Hematoxylin and eosin (H E) and luxol fast blue (LFB) staining of spinal cord tissue 30 days after EAE modeling, with or without treatment. Arrows point to pink areas indicative of inflammatory infiltration. The intensity of blue color in the LFB images represents the degree of demyelination (lighter = greater demyelination). Mag = magnification of specific areas of interest in LFB images. Scale bar = 100 μm for H E and 50 μm for LFB. For (B,C) , the data are presented as the mean ± SD ( n = 6), * p

Techniques Used: In Vivo, Mouse Assay, Western Blot, Expressing, Staining

Immunofluorescence of SphK1 and SphK2 in spinal cord tissues of mice induced by EAE. Mice subjected to EAE modeling were treated with vehicle (physiological saline), Dab, or PAR-1-inh. Tissues were stained for (A) SphK1 and (B) SphK2 in green and nuclei (DAPI) in blue. Scale bar = 100 μm. Green fluorescence was quantified by measuring the relative mean IOD. The data are presented as the mean ± SD ( n = 6), * p
Figure Legend Snippet: Immunofluorescence of SphK1 and SphK2 in spinal cord tissues of mice induced by EAE. Mice subjected to EAE modeling were treated with vehicle (physiological saline), Dab, or PAR-1-inh. Tissues were stained for (A) SphK1 and (B) SphK2 in green and nuclei (DAPI) in blue. Scale bar = 100 μm. Green fluorescence was quantified by measuring the relative mean IOD. The data are presented as the mean ± SD ( n = 6), * p

Techniques Used: Immunofluorescence, Mouse Assay, Staining, Fluorescence

2) Product Images from "Dabigatran Suppresses PAR-1/SphK/S1P Activation of Astrocytes in Experimental Autoimmune Encephalomyelitis Model"

Article Title: Dabigatran Suppresses PAR-1/SphK/S1P Activation of Astrocytes in Experimental Autoimmune Encephalomyelitis Model

Journal: Frontiers in Molecular Neuroscience

doi: 10.3389/fnmol.2020.00114

Gene and protein expression of components of the PAR-1/SphK/S1P axis. qRT-PCR analysis of the gene expression of (A) PAR-1, (B) S1PR1, (C) SphK1, and (D) SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for 0 h, 1 h, or 6 h. Western blot detection and quantification of the protein expression of PAR-1, S1PR1, SphK1, and SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for (E) 0 h, (F) 1 h, or (G) 6 h. The data are presented as the mean ± SD ( n = 3), * p
Figure Legend Snippet: Gene and protein expression of components of the PAR-1/SphK/S1P axis. qRT-PCR analysis of the gene expression of (A) PAR-1, (B) S1PR1, (C) SphK1, and (D) SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for 0 h, 1 h, or 6 h. Western blot detection and quantification of the protein expression of PAR-1, S1PR1, SphK1, and SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for (E) 0 h, (F) 1 h, or (G) 6 h. The data are presented as the mean ± SD ( n = 3), * p

Techniques Used: Expressing, Quantitative RT-PCR, Western Blot

Construction of the in vivo experimental autoimmune encephalomyelitis (EAE) model. Experimental mice were induced by EAE and treated with physiological saline (vehicle), 10 mg/g Dab, or 10 μg/kg PAR-1-inh. (A) Clinical evaluation of neurological function was carried out daily for over 30 days. 0, unaffected; 1, tail limpness; 2, failure on attempt to roll over; 3, partial paralysis; 4, complete paralysis, and 5, moribund. Data are presented as the mean ± SD of six replicates. Western blot evaluation and quantification of the protein expression of (B) IL-1β, S1P, (C) SphK1, and SphK2 in spinal cord tissues after 30 days of EAE modeling, with or without treatment. (D) Hematoxylin and eosin (H E) and luxol fast blue (LFB) staining of spinal cord tissue 30 days after EAE modeling, with or without treatment. Arrows point to pink areas indicative of inflammatory infiltration. The intensity of blue color in the LFB images represents the degree of demyelination (lighter = greater demyelination). Mag = magnification of specific areas of interest in LFB images. Scale bar = 100 μm for H E and 50 μm for LFB. For (B,C) , the data are presented as the mean ± SD ( n = 6), * p
Figure Legend Snippet: Construction of the in vivo experimental autoimmune encephalomyelitis (EAE) model. Experimental mice were induced by EAE and treated with physiological saline (vehicle), 10 mg/g Dab, or 10 μg/kg PAR-1-inh. (A) Clinical evaluation of neurological function was carried out daily for over 30 days. 0, unaffected; 1, tail limpness; 2, failure on attempt to roll over; 3, partial paralysis; 4, complete paralysis, and 5, moribund. Data are presented as the mean ± SD of six replicates. Western blot evaluation and quantification of the protein expression of (B) IL-1β, S1P, (C) SphK1, and SphK2 in spinal cord tissues after 30 days of EAE modeling, with or without treatment. (D) Hematoxylin and eosin (H E) and luxol fast blue (LFB) staining of spinal cord tissue 30 days after EAE modeling, with or without treatment. Arrows point to pink areas indicative of inflammatory infiltration. The intensity of blue color in the LFB images represents the degree of demyelination (lighter = greater demyelination). Mag = magnification of specific areas of interest in LFB images. Scale bar = 100 μm for H E and 50 μm for LFB. For (B,C) , the data are presented as the mean ± SD ( n = 6), * p

Techniques Used: In Vivo, Mouse Assay, Western Blot, Expressing, Staining

Immunofluorescence of SphK1 and SphK2 in spinal cord tissues of mice induced by EAE. Mice subjected to EAE modeling were treated with vehicle (physiological saline), Dab, or PAR-1-inh. Tissues were stained for (A) SphK1 and (B) SphK2 in green and nuclei (DAPI) in blue. Scale bar = 100 μm. Green fluorescence was quantified by measuring the relative mean IOD. The data are presented as the mean ± SD ( n = 6), * p
Figure Legend Snippet: Immunofluorescence of SphK1 and SphK2 in spinal cord tissues of mice induced by EAE. Mice subjected to EAE modeling were treated with vehicle (physiological saline), Dab, or PAR-1-inh. Tissues were stained for (A) SphK1 and (B) SphK2 in green and nuclei (DAPI) in blue. Scale bar = 100 μm. Green fluorescence was quantified by measuring the relative mean IOD. The data are presented as the mean ± SD ( n = 6), * p

Techniques Used: Immunofluorescence, Mouse Assay, Staining, Fluorescence

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96
    Novus Biologicals anti sphk1 antibody
    Gene and protein expression of components of the PAR-1/SphK/S1P axis. qRT-PCR analysis of the gene expression of (A) PAR-1, (B) S1PR1, (C) <t>SphK1,</t> and (D) SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for 0 h, 1 h, or 6 h. Western blot detection and quantification of the protein expression of PAR-1, S1PR1, SphK1, and SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for (E) 0 h, (F) 1 h, or (G) 6 h. The data are presented as the mean ± SD ( n = 3), * p
    Anti Sphk1 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 96/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti sphk1 antibody/product/Novus Biologicals
    Average 96 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    anti sphk1 antibody - by Bioz Stars, 2022-10
    96/100 stars
      Buy from Supplier

    90
    Novus Biologicals anti s1p1
    Human T-LBLs Undergo Autophagy and Overexpress BCL2α, <t>S1P1</t> and ICAM1 (A) Western blot showing protein levels of MCL1, BCLXL, BCL2α, LC3-I, LC3-II, BECLIN 1, S1P1, and ACTIN in six T-LBL versus six T-ALL human patient samples. (B) Western blot showing the levels of ICAM1, LFA1, E-Cad, N-Cad, CD99, and ACTIN in 6 T-LBL versus 6 T-ALL human patient samples. (C) Gene expression profiling of human T-LBL and T-ALL samples shows that BCL2α .
    Anti S1p1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti s1p1/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti s1p1 - by Bioz Stars, 2022-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    Gene and protein expression of components of the PAR-1/SphK/S1P axis. qRT-PCR analysis of the gene expression of (A) PAR-1, (B) S1PR1, (C) SphK1, and (D) SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for 0 h, 1 h, or 6 h. Western blot detection and quantification of the protein expression of PAR-1, S1PR1, SphK1, and SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for (E) 0 h, (F) 1 h, or (G) 6 h. The data are presented as the mean ± SD ( n = 3), * p

    Journal: Frontiers in Molecular Neuroscience

    Article Title: Dabigatran Suppresses PAR-1/SphK/S1P Activation of Astrocytes in Experimental Autoimmune Encephalomyelitis Model

    doi: 10.3389/fnmol.2020.00114

    Figure Lengend Snippet: Gene and protein expression of components of the PAR-1/SphK/S1P axis. qRT-PCR analysis of the gene expression of (A) PAR-1, (B) S1PR1, (C) SphK1, and (D) SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for 0 h, 1 h, or 6 h. Western blot detection and quantification of the protein expression of PAR-1, S1PR1, SphK1, and SphK2 in astrocytes treated with LPS or thrombin, with or without Dab or PAR-1-inh (LPS only), for (E) 0 h, (F) 1 h, or (G) 6 h. The data are presented as the mean ± SD ( n = 3), * p

    Article Snippet: The cells were then blocked with 5% bovine serum albumin at 37°C for 1 h and incubated overnight at 4°C with primary antibodies against GFAP (mouse, 1:100, ab10062, Abcam, Cambridge, UK), PAR-1 (mouse, 1:100, NB1-71770-SS, Novus Biologicals, Centennial, CO, USA), S1P receptor 1 (S1PR1, rabbit, 1:150, NB120-11424, Novus Biologicals), SphK1 (rabbit, 1:50, ab71700, Abcam), and SphK2 (rabbit, 1:100, 1-SP030-02, Quartett, Berlin, Germany).

    Techniques: Expressing, Quantitative RT-PCR, Western Blot

    Construction of the in vivo experimental autoimmune encephalomyelitis (EAE) model. Experimental mice were induced by EAE and treated with physiological saline (vehicle), 10 mg/g Dab, or 10 μg/kg PAR-1-inh. (A) Clinical evaluation of neurological function was carried out daily for over 30 days. 0, unaffected; 1, tail limpness; 2, failure on attempt to roll over; 3, partial paralysis; 4, complete paralysis, and 5, moribund. Data are presented as the mean ± SD of six replicates. Western blot evaluation and quantification of the protein expression of (B) IL-1β, S1P, (C) SphK1, and SphK2 in spinal cord tissues after 30 days of EAE modeling, with or without treatment. (D) Hematoxylin and eosin (H E) and luxol fast blue (LFB) staining of spinal cord tissue 30 days after EAE modeling, with or without treatment. Arrows point to pink areas indicative of inflammatory infiltration. The intensity of blue color in the LFB images represents the degree of demyelination (lighter = greater demyelination). Mag = magnification of specific areas of interest in LFB images. Scale bar = 100 μm for H E and 50 μm for LFB. For (B,C) , the data are presented as the mean ± SD ( n = 6), * p

    Journal: Frontiers in Molecular Neuroscience

    Article Title: Dabigatran Suppresses PAR-1/SphK/S1P Activation of Astrocytes in Experimental Autoimmune Encephalomyelitis Model

    doi: 10.3389/fnmol.2020.00114

    Figure Lengend Snippet: Construction of the in vivo experimental autoimmune encephalomyelitis (EAE) model. Experimental mice were induced by EAE and treated with physiological saline (vehicle), 10 mg/g Dab, or 10 μg/kg PAR-1-inh. (A) Clinical evaluation of neurological function was carried out daily for over 30 days. 0, unaffected; 1, tail limpness; 2, failure on attempt to roll over; 3, partial paralysis; 4, complete paralysis, and 5, moribund. Data are presented as the mean ± SD of six replicates. Western blot evaluation and quantification of the protein expression of (B) IL-1β, S1P, (C) SphK1, and SphK2 in spinal cord tissues after 30 days of EAE modeling, with or without treatment. (D) Hematoxylin and eosin (H E) and luxol fast blue (LFB) staining of spinal cord tissue 30 days after EAE modeling, with or without treatment. Arrows point to pink areas indicative of inflammatory infiltration. The intensity of blue color in the LFB images represents the degree of demyelination (lighter = greater demyelination). Mag = magnification of specific areas of interest in LFB images. Scale bar = 100 μm for H E and 50 μm for LFB. For (B,C) , the data are presented as the mean ± SD ( n = 6), * p

    Article Snippet: The cells were then blocked with 5% bovine serum albumin at 37°C for 1 h and incubated overnight at 4°C with primary antibodies against GFAP (mouse, 1:100, ab10062, Abcam, Cambridge, UK), PAR-1 (mouse, 1:100, NB1-71770-SS, Novus Biologicals, Centennial, CO, USA), S1P receptor 1 (S1PR1, rabbit, 1:150, NB120-11424, Novus Biologicals), SphK1 (rabbit, 1:50, ab71700, Abcam), and SphK2 (rabbit, 1:100, 1-SP030-02, Quartett, Berlin, Germany).

    Techniques: In Vivo, Mouse Assay, Western Blot, Expressing, Staining

    Immunofluorescence of SphK1 and SphK2 in spinal cord tissues of mice induced by EAE. Mice subjected to EAE modeling were treated with vehicle (physiological saline), Dab, or PAR-1-inh. Tissues were stained for (A) SphK1 and (B) SphK2 in green and nuclei (DAPI) in blue. Scale bar = 100 μm. Green fluorescence was quantified by measuring the relative mean IOD. The data are presented as the mean ± SD ( n = 6), * p

    Journal: Frontiers in Molecular Neuroscience

    Article Title: Dabigatran Suppresses PAR-1/SphK/S1P Activation of Astrocytes in Experimental Autoimmune Encephalomyelitis Model

    doi: 10.3389/fnmol.2020.00114

    Figure Lengend Snippet: Immunofluorescence of SphK1 and SphK2 in spinal cord tissues of mice induced by EAE. Mice subjected to EAE modeling were treated with vehicle (physiological saline), Dab, or PAR-1-inh. Tissues were stained for (A) SphK1 and (B) SphK2 in green and nuclei (DAPI) in blue. Scale bar = 100 μm. Green fluorescence was quantified by measuring the relative mean IOD. The data are presented as the mean ± SD ( n = 6), * p

    Article Snippet: The cells were then blocked with 5% bovine serum albumin at 37°C for 1 h and incubated overnight at 4°C with primary antibodies against GFAP (mouse, 1:100, ab10062, Abcam, Cambridge, UK), PAR-1 (mouse, 1:100, NB1-71770-SS, Novus Biologicals, Centennial, CO, USA), S1P receptor 1 (S1PR1, rabbit, 1:150, NB120-11424, Novus Biologicals), SphK1 (rabbit, 1:50, ab71700, Abcam), and SphK2 (rabbit, 1:100, 1-SP030-02, Quartett, Berlin, Germany).

    Techniques: Immunofluorescence, Mouse Assay, Staining, Fluorescence

    Human T-LBLs Undergo Autophagy and Overexpress BCL2α, S1P1 and ICAM1 (A) Western blot showing protein levels of MCL1, BCLXL, BCL2α, LC3-I, LC3-II, BECLIN 1, S1P1, and ACTIN in six T-LBL versus six T-ALL human patient samples. (B) Western blot showing the levels of ICAM1, LFA1, E-Cad, N-Cad, CD99, and ACTIN in 6 T-LBL versus 6 T-ALL human patient samples. (C) Gene expression profiling of human T-LBL and T-ALL samples shows that BCL2α .

    Journal: Cancer cell

    Article Title: T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1 and ICAM1 Leading to a Blockade of Tumor Cell Intravasation

    doi: 10.1016/j.ccr.2010.09.009

    Figure Lengend Snippet: Human T-LBLs Undergo Autophagy and Overexpress BCL2α, S1P1 and ICAM1 (A) Western blot showing protein levels of MCL1, BCLXL, BCL2α, LC3-I, LC3-II, BECLIN 1, S1P1, and ACTIN in six T-LBL versus six T-ALL human patient samples. (B) Western blot showing the levels of ICAM1, LFA1, E-Cad, N-Cad, CD99, and ACTIN in 6 T-LBL versus 6 T-ALL human patient samples. (C) Gene expression profiling of human T-LBL and T-ALL samples shows that BCL2α .

    Article Snippet: The primary antibodies included anti-BCL2, anti-CD3, anti-CD4, and anti-CD8 (Santa Cruz), anti-BCLXL (BD Biosciences), anti-MCL1 (BD Biosciences), anti-LC3 (MBL International Co.), anti-LC3β (Abcam), anti-BECLIN1 (ANASPEC Inc.), anti-S1P1 (Novus Biologicals), anti-AKT, anti-phosph Ser473-AKT, anti-ICAM1, anti-N-Cadherin, anti-E-Cadherin (Cell Signaling), anti-LFA1 (LifeSpan Biosciences), and anti-ACTIN (Sigma) antibodies.

    Techniques: Western Blot, Expressing

    The Selective S1P1 Antagonist W146 Promotes Intravasation of Bcl -2-overexpressing T-LBL cells in vivo (A) Schematic drawing of the experimental strategy. (B-G) Confocal images of EGFP-labeled blood vessels (B, E), dsRED2-labeled lymphoma cells (C,F), and the merged images of a vehicle-treated (D; n=29) and a W146-treated transplanted animal (G; n=18) demonstrate that W146 treatment promotes intravasation of bcl-2 -overexpressing lymphoma cells (arrowheads) in vivo (compare panel G to D). Note that W146 treatment also inhibited the in vivo formation of lymphoma cell aggregates (compare panel F to C). Scale bar for panels B-G = 10 μM.

    Journal: Cancer cell

    Article Title: T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1 and ICAM1 Leading to a Blockade of Tumor Cell Intravasation

    doi: 10.1016/j.ccr.2010.09.009

    Figure Lengend Snippet: The Selective S1P1 Antagonist W146 Promotes Intravasation of Bcl -2-overexpressing T-LBL cells in vivo (A) Schematic drawing of the experimental strategy. (B-G) Confocal images of EGFP-labeled blood vessels (B, E), dsRED2-labeled lymphoma cells (C,F), and the merged images of a vehicle-treated (D; n=29) and a W146-treated transplanted animal (G; n=18) demonstrate that W146 treatment promotes intravasation of bcl-2 -overexpressing lymphoma cells (arrowheads) in vivo (compare panel G to D). Note that W146 treatment also inhibited the in vivo formation of lymphoma cell aggregates (compare panel F to C). Scale bar for panels B-G = 10 μM.

    Article Snippet: The primary antibodies included anti-BCL2, anti-CD3, anti-CD4, and anti-CD8 (Santa Cruz), anti-BCLXL (BD Biosciences), anti-MCL1 (BD Biosciences), anti-LC3 (MBL International Co.), anti-LC3β (Abcam), anti-BECLIN1 (ANASPEC Inc.), anti-S1P1 (Novus Biologicals), anti-AKT, anti-phosph Ser473-AKT, anti-ICAM1, anti-N-Cadherin, anti-E-Cadherin (Cell Signaling), anti-LFA1 (LifeSpan Biosciences), and anti-ACTIN (Sigma) antibodies.

    Techniques: In Vivo, Labeling

    Bcl-2 -Overexpressing T-LBL Cells Display Increased Aggregation That Can Be Overcome by Akt Activation and S1P1 Inhibition in-vitro (A) Schematic of the experimental strategy. (B-E) Brightfield images of lymphoma or leukemic tumor cells in culture for 7 days on ZKS stroma: (B) Myc;Cre T-LBL, (C) Myc;Cre;bcl-2 T-LBL, (D) Myc;Cre;bcl-2 T-ALL, or (E) Myc;Cre;bcl-2;Myr-Akt2 T-ALL cells. (F) Quantification of aggregates over free cells for tumor cell culture on ZKS cells under normal conditions for 7 days: Myc;Cre T-LBL (n=10), Myc;Cre;bcl-2 T-LBL (n=11), Myc;Cre;bcl-2 T-ALL (n=13), or Myc;Cre;bcl-2;Myr-Akt2 T-ALL (n=11) transgenic fish. (G-J) The formation of homotypic cell aggregation of Myc;Cre;bcl-2 T-LBL cells is inhibited after treatment with a specific S1P1 antagonist W146 (1μM, 5μM, and 50μM) in ZKS stroma supported cell culture. (K) Ratio of cell aggregates to free cells in Myc;Cre;bcl-2 .

    Journal: Cancer cell

    Article Title: T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1 and ICAM1 Leading to a Blockade of Tumor Cell Intravasation

    doi: 10.1016/j.ccr.2010.09.009

    Figure Lengend Snippet: Bcl-2 -Overexpressing T-LBL Cells Display Increased Aggregation That Can Be Overcome by Akt Activation and S1P1 Inhibition in-vitro (A) Schematic of the experimental strategy. (B-E) Brightfield images of lymphoma or leukemic tumor cells in culture for 7 days on ZKS stroma: (B) Myc;Cre T-LBL, (C) Myc;Cre;bcl-2 T-LBL, (D) Myc;Cre;bcl-2 T-ALL, or (E) Myc;Cre;bcl-2;Myr-Akt2 T-ALL cells. (F) Quantification of aggregates over free cells for tumor cell culture on ZKS cells under normal conditions for 7 days: Myc;Cre T-LBL (n=10), Myc;Cre;bcl-2 T-LBL (n=11), Myc;Cre;bcl-2 T-ALL (n=13), or Myc;Cre;bcl-2;Myr-Akt2 T-ALL (n=11) transgenic fish. (G-J) The formation of homotypic cell aggregation of Myc;Cre;bcl-2 T-LBL cells is inhibited after treatment with a specific S1P1 antagonist W146 (1μM, 5μM, and 50μM) in ZKS stroma supported cell culture. (K) Ratio of cell aggregates to free cells in Myc;Cre;bcl-2 .

    Article Snippet: The primary antibodies included anti-BCL2, anti-CD3, anti-CD4, and anti-CD8 (Santa Cruz), anti-BCLXL (BD Biosciences), anti-MCL1 (BD Biosciences), anti-LC3 (MBL International Co.), anti-LC3β (Abcam), anti-BECLIN1 (ANASPEC Inc.), anti-S1P1 (Novus Biologicals), anti-AKT, anti-phosph Ser473-AKT, anti-ICAM1, anti-N-Cadherin, anti-E-Cadherin (Cell Signaling), anti-LFA1 (LifeSpan Biosciences), and anti-ACTIN (Sigma) antibodies.

    Techniques: Activation Assay, Inhibition, In Vitro, Cell Culture, Transgenic Assay, Fluorescence In Situ Hybridization

    Immunohistochemical analysis of BCL2 and S1P1 in human T-LBL and T-ALL (A-F) Human BCL2 detected by immunohistochemistry in normal thymus (A,D) and in samples from patients with T-LBL (B,E) or T-ALL (C,F). Panels D-F are magnified views of boxes in A-C, respectively, and insets show individual cells including a mature thymocyte with high BCL2 expression. (G-L) Human S1P1 detected by immunohistochemistry in normal thymus (G,J) and in samples from patients with T-LBL (H,K) and T-ALL (I,L). Panels J-L are magnified views of boxes in G-I, respectively. Note the reciprocal expression pattern of BCL2 and S1P1 in the thymic cortex and medulla regions. The thick arrow in panel (A,G) shows the thymic medulla region, while thin arrows in panels (D-F) indicate mature thymocytes with high BCL2 expression, Arrowheads in panels (J-L) show the S1P1 .

    Journal: Cancer cell

    Article Title: T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1 and ICAM1 Leading to a Blockade of Tumor Cell Intravasation

    doi: 10.1016/j.ccr.2010.09.009

    Figure Lengend Snippet: Immunohistochemical analysis of BCL2 and S1P1 in human T-LBL and T-ALL (A-F) Human BCL2 detected by immunohistochemistry in normal thymus (A,D) and in samples from patients with T-LBL (B,E) or T-ALL (C,F). Panels D-F are magnified views of boxes in A-C, respectively, and insets show individual cells including a mature thymocyte with high BCL2 expression. (G-L) Human S1P1 detected by immunohistochemistry in normal thymus (G,J) and in samples from patients with T-LBL (H,K) and T-ALL (I,L). Panels J-L are magnified views of boxes in G-I, respectively. Note the reciprocal expression pattern of BCL2 and S1P1 in the thymic cortex and medulla regions. The thick arrow in panel (A,G) shows the thymic medulla region, while thin arrows in panels (D-F) indicate mature thymocytes with high BCL2 expression, Arrowheads in panels (J-L) show the S1P1 .

    Article Snippet: The primary antibodies included anti-BCL2, anti-CD3, anti-CD4, and anti-CD8 (Santa Cruz), anti-BCLXL (BD Biosciences), anti-MCL1 (BD Biosciences), anti-LC3 (MBL International Co.), anti-LC3β (Abcam), anti-BECLIN1 (ANASPEC Inc.), anti-S1P1 (Novus Biologicals), anti-AKT, anti-phosph Ser473-AKT, anti-ICAM1, anti-N-Cadherin, anti-E-Cadherin (Cell Signaling), anti-LFA1 (LifeSpan Biosciences), and anti-ACTIN (Sigma) antibodies.

    Techniques: Immunohistochemistry, Expressing